Home > News > Company news

Strategic Cooperation Agreement Reached between Tomophase Incorporation and Guangzhou Institute of Respiratory Disease

2014-04-28 10:46:47 Tomophase Read

Guangzhou, China – April 28, 2014 – Tomophase Incorporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that Tomophase Incorporation and Guangzhou Institute of Respiratory Disease (GIRD), the State Key Laboratory of China has signed the strategic cooperation agreement in Guangzhou, china.

The Strategic planning is mainly to promote the OCT technology in respiratory diseases. Aimed to develop and apply the device in the disease detection treatment of asthma and chronic obstructive pulmonary as a standard equipment. And two years later, the device can be used for the research and treatment of early stage lung cancer, as the world's leading technology.


About GIRD

Guangzhou Institute of Respiratory Disease (GIRD), founded in 1979, located in the beautiful Pearl River shore, is the earliest of the Institute of Respiratory Diseases established in China. Adhering to the wave of reform and opening era, supported by Guangdong Provincial Department of Science and Technology, Guangdong Provincial Department of Health & Guangzhou Medical College, GIRD always adhere to focus on research in respiratory diseases, and gradually become a professional base in the scientific research, medical and personnel training for pulmonology. GIRD is also the State Key Laboratory of Respiratory Disease and postdoctoral workstation of internal medicine of China.

About Tomophase

Tomophase is a leader in developing bronchoscopic-based systems for interventional pulmonology. Offering significantly higher resolution than either CT scan or ultrasound, OCTIS provides real-time, high resolution, sub-surface tissue imaging of airways and lungs, to be followed by diagnostic and therapeutic applications. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. The company has 15 patent and applications issued and pending. FDA 510(k) clearance for OCTIS was received and the CE Mark is expected in 2015. The U.S. commercial launch is underway and the EU rollout is proceeding. The company is currently raising investment capital to meet the increasing international demand for the OCT Imaging System. Examples of our tissueimaging results are available at